KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inovio Pharmaceuticals (INO) Shares Outstanding (2016 - 2025)

Historic Shares Outstanding for Inovio Pharmaceuticals (INO) over the last 17 years, with Q3 2025 value amounting to $53.6 million.

  • Inovio Pharmaceuticals' Shares Outstanding rose 10563.01% to $53.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $53.6 million, marking a year-over-year increase of 10563.01%. This contributed to the annual value of $36.1 million for FY2024, which is 5838.14% up from last year.
  • According to the latest figures from Q3 2025, Inovio Pharmaceuticals' Shares Outstanding is $53.6 million, which was up 10563.01% from $36.7 million recorded in Q2 2025.
  • Over the past 5 years, Inovio Pharmaceuticals' Shares Outstanding peaked at $268.1 million during Q2 2023, and registered a low of $18.1 million during Q4 2021.
  • For the 5-year period, Inovio Pharmaceuticals' Shares Outstanding averaged around $103.5 million, with its median value being $36.7 million (2025).
  • In the last 5 years, Inovio Pharmaceuticals' Shares Outstanding plummeted by 9099.04% in 2023 and then soared by 10563.01% in 2025.
  • Inovio Pharmaceuticals' Shares Outstanding (Quarter) stood at $18.1 million in 2021, then grew by 16.43% to $21.1 million in 2022, then rose by 8.07% to $22.8 million in 2023, then surged by 58.38% to $36.1 million in 2024, then soared by 48.4% to $53.6 million in 2025.
  • Its last three reported values are $53.6 million in Q3 2025, $36.7 million for Q2 2025, and $36.7 million during Q1 2025.